PATUSKY CHRISTOPHER 4

What Happened
Christopher Patusky, a director of United Therapeutics (UTHR), exercised 1,000 stock options at $101.80 per share (cost $101,800) and sold 1,000 shares in an open-market sale at $578.88 per share (proceeds $578,880) on April 17, 2026. The net proceeds before taxes and fees were roughly $477,080. The filing also reports a related derivative conversion/disposition entry for 1,000 shares at $0.00 as part of the exercise/sale reporting.

Key Details

• Transaction date: 2026-04-17
• Exercise: 1,000 shares exercised at $101.80 each (total $101,800) — transaction code M
• Sale: 1,000 shares sold open market at $578.88 each (total $578,880) — transaction code S
• Additional entry: 1,000-share derivative disposition reported at $0.00 (code M) as part of the exercise/reporting sequence
• Footnote: Exercise and immediate sale were made pursuant to a Rule 10b5-1 trading plan entered December 18, 2025
• Shares owned after the transaction: not stated in the provided filing summary
• Filing timeliness: filed and dated 2026-04-17 (timely)

Context
This was an option exercise followed by an immediate sale (a common cashless exercise pattern) reported under a pre-established 10b5-1 plan, which sets predetermined trades and reduces concerns about trading on nonpublic information. Sales are routine for insiders to realize gains or cover option exercise costs; they do not by themselves indicate a change in company outlook.